Business Context and Reporting Period
This Form 8-K Current Report was filed by Nephros, Inc. on April 15, 2015. The filing primarily addresses Item 5.02 regarding the departure of certain officers and the appointment of new leadership. The company is incorporated in Delaware and is based in River Edge, New Jersey.
Key Financial Metrics
This filing does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The document focuses exclusively on executive compensation and corporate governance changes.
Material Changes
- Executive Appointment: Daron Evans was appointed President, Chief Executive Officer, and Acting Chief Financial Officer, effective April 15, 2015.
- Executive Departure: Paul A. Mieyal resigned from his roles as Acting President, CEO, and CFO. He remains a member of the Board of Directors.
- Board Changes: Daron Evans resigned as Chairman of the Board. Lawrence J. Centella was appointed Chairman of the Board.
Compensation, Outlook, and Risks
Employment Agreement Terms
Mr. Evans signed a four-year employment agreement expiring April 14, 2019. Key terms include:
- Base Salary: $240,000 annualized.
- Performance Bonus: Eligible for up to 30% of base salary.
- Stock Options: Granted options to purchase 2,184,193 shares at $0.60 per share (closing price on the effective date).
- Vesting Schedule:
- 35% vests in 16 equal quarterly installments starting June 30, 2015.
- 15% vests upon approval of listing on a national securities exchange (e.g., NASDAQ, NYSE).
- 10% vests if annual revenue exceeds $3,000,000.
- 20% vests if annual revenue exceeds $6,000,000.
- 20% vests if annual revenue exceeds $10,000,000.
- Severance: 3 months of base salary if terminated without cause within the first year; 6 months if terminated after the first year.
Outlook and Risks
The vesting of a significant portion of Mr. Evans' equity compensation is contingent upon the company achieving specific revenue milestones ($3M, $6M, and $10M) and securing a listing on a national securities exchange. The filing does not provide specific guidance on when these milestones are expected to be met.
Investor Verification Checklist
- Verify the current status of Nephros, Inc.'s application for listing on a national securities exchange (NASDAQ or NYSE), as this triggers 15% of the CEO's option vesting.
- Review the company's most recent financial statements (e.g., 10-K or 10-Q) to assess current revenue levels against the $3M, $6M, and $10M vesting thresholds.
- Confirm the total outstanding share count to evaluate the dilution impact of the 2,184,193 new options granted to Mr. Evans.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason" regarding termination.